NCT01487096View on ClinicalTrials.gov

Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

PHASE2CompletedINTERVENTIONAL
Enrollment

179

Participants

Timeline

Start Date

April 30, 2001

Primary Completion Date

March 31, 2003

Study Completion Date

March 31, 2003

Conditions
Multiple Sclerosis
Interventions
DRUG

Teriflunomide

"film-coated tablet~oral administration"

DRUG

Placebo (placebo for teriflunomide)

"film-coated tablet~oral administration"

Trial Locations (2)

Unknown

Canada, Toronto

sanofi-aventis France, Lyon

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT01487096 - Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses | Biotech Hunter | Biotech Hunter